Skip main navigation

Main contents starts here

More about Grange Castle

The decision to locate Takeda's new worldwide centre for Active Pharmaceutical Ingredient (API) manufacturing, development and technical support in Ireland represents a key strategic addition to the group's global production network. Located at the high technology Pharmaceutical and Biotechnology Business Park at Grange Castle in Clondalkin Dublin Takeda Ireland Ltd. (Grange Castle) is Takeda's first API plant constructed outside Japan.

Takeda Ireland Ltd - Grange Castle will be the launch vehicle for new strategic products for global markets developing and producing API's from clinical trial stages through to launch and full commercialisation. In our new multipurpose plant we plan to develop for clinical trial supply new products each year, while also supplying world markets with existing blockbuster products such as pioglitazone (brand name: Actos).

We rely on our world-class staff, equipment and systems to meet the challenge of competing in our leading edge markets. Our role includes responsibility for process R&D and technology transfer, which supplement our global supply requirements.

Company History & Future Plan
2002: Takeda Pharma Ireland Limited established
2002: Facility Design, Environmental Impact Study & Planning Permission
2003-2006: Construction, Commissioning & Validation of API Facility
2007: Start of commercial production
2008: FDA Approval
2009: Irish Medicines Board Wholesale License Approval
2009: Integration of Takeda Pharma Ireland Limited into Takeda Ireland Ltd. (Grange Castle)
2011: Completion of Administration Building Expansion

Skip side navigation

LinkedIn

Skip sub navigation

Page Top